ASSESSING ADEQUATE P2Y12 PLATELET INHIBITION BY THE ACCUMETRICS VERIFYNOW ASSAY USING “PLATELET REACTIVITY UNITS” OR “PERCENT INHIBITION”: FINDINGS FROM A REAL WORLD REGISTRY  by Muhlestein, J. Brent et al.
E1254
JACC April 5, 2011
Volume 57, Issue 14
  QUALITY OF CARE AND OUTCOMES ASSESSMENT 
ASSESSING ADEQUATE P2Y12 PLATELET INHIBITION BY THE ACCUMETRICS VERIFYNOW ASSAY USING 
“PLATELET REACTIVITY UNITS” OR “PERCENT INHIBITION”: FINDINGS FROM A REAL WORLD REGISTRY
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Monday, April 04, 2011, 3:30 p.m.-4:45 p.m.
Session Title: Information Technology from Bench to Bedside
Abstract Category: 45. Biomedical Computing/Information Technology
Session-Poster Board Number: 1135-140
Authors: J. Brent Muhlestein, Heidi T. May, Donald L. Lappé, Sterling T. Bennett, Brian K. Whisenant, Jeffrey L. Anderson, Intermountain Medical 
Center, Murray, UT, University of Utah, Salt Lake City, UT
Background:  Many pts receiving P2Y12 ADP antiplatelet therapy have inadequate levels of platelet inhibition and this results in increased CV 
risk. A method to test the adequacy of P2Y12 platelet inhibition is the Accumetrics VerifyNow (VN) assay. This assay reports 2 results:  1) Platelet 
reactivity units (PRU): measures the absolute reactivity of platelets when stimulated by ADP; 2) Percent inhibition (PI): a ratio of ADP stimulated 
platelet inhibition and a “base” result which is obtained through ADP-independent TRAP stimulation. The company’s original recommendation was to 
use the PI result with a threshold of 50% to determine adequate inhibition. In a “real world” situation, which result is best remains uncertain.
Methods:  To compare the performance of both the PRU and PI results, 89 pts receiving P2Y12 inhibition using the VN assay were studied. 
Correlations were made between PRU and PI based on adequacy of platelet inhibition targets of ≤235 PRU or ≥50% PI, respectively.
Results:  Age averaged 63±13 yrs and 35% were female. Only 23% of pts were adequately platelet inhibited by PI compared to 52% by PRU 
(Figure). A total of 14 (16%) pts had a base result greater than the PRU result.
Conclusions:  During real world use of the VN assay for P2Y12 inhibition, in more than half of the instances in which PRU reached the target of ≤ 
235, a PI result of <50% was obtained. This appears to be due to an error in the base assay result. Because of this and the fact that most outcomes 
trials are based on PRU results, we do not recommend using PI. 
